…a new quality guarantee for training providers in France.
The quality certification has been issued for the following category of action TRAINING ACTIVITIES.
This certification complies with the law of 5 September 2018 “for the freedom to choose one’s professional future”, which imposes mandatory certification according to a single national reference system. Training is a major stake for the quality assurance policies, particularly in the highly regulated sector of clinical research. It is also a key factor in maximising productivity. We provide an expert team to guide and train you.
to be independent in designing and configure an eCRF and/or in configuring the related administrative environment. These training courses firstly target data managers and project managers.
enables investigators, CRAs (Clinical Research Assistants), CSTs (Clinical Studies Technicians), etc., to use the software features in an autonomous way.
This training activity is registered under number 11 92 19676 92. It is part of continuous training actions according to the articles L 6313-1 to L 6313-11 of the French Employment Code. It provides financial assistance in the name of continuous professional training.
Med City News This month, the World Health Organization released new guidelines on the ethics and governance of large language models (LLMs) in healthcare. Reactions from the leaders of healthcare AI companies have been mainly positive. In its guidance, WHO outlined five broad applications for LLMS in healthcare: diagnosis and clinical care, administrative tasks, education, […]
Applied Clinical Trials Online Patient safety event reports (PSEs) play an integral role in hospitals for keeping accurate records of adverse events (AEs). A challenge faced by hospitals is efficiently and accurately classifying these AEs due to the sheer number of reports that are created. A recent study published in JMIR turned to machine learning […]
International Biopharma The growing uptake of decentralised clinical trials in recent years reflects several key drivers such as advances in remote monitoring technology and data analytics, the need to access broader, more diverse trial populations, and demand in clinical development for cost efficiencies and meaningful, real world study outcomes. However, we are at a point […]